Dr. Jordi Monés, MD, PhD, the Director and Ophthalmologist specialising in macula, retina and vitreous at the Barcelona Macula Foundation, will attend the “International Symposium on Ocular Pharmacology and Therapeutics (ISOPT)” in the Icelandic capital of Reykjavik from 19-22 June.
Dr. Monés participates at the Symposium as the Session Chair of Retina, together with Dr. Baruch D. Kuppermann, a member of the Barcelona Macula Foundation’s Scientific Advisory Board.
Dr. Monés will also take the Chair of Dry AMD and will set out “The MAHALO Phase II Results: Lampalizumab (Anti-factor D) in Patients with Geographic Atrophy”. MAHALO is the first study to show a positive treatment effect in combating geographic atrophy caused by Atrophic Macular Degeneration.
Meanwhile, Dr. Baruch D. Kuppermann will expound on “Anti-VEGF Treatments for Diabetic Macular Edema: Comparison of Phase III Randomized Controlled Clinical Studies”, which compares various clinical studies on diabetic macular edema.
Over recent years, the “International Symposium on Ocular Pharmacology and Therapeutics” has become a meeting point for debating the breakthroughs in ophthalmological techniques and medicines. The intention is to promote research and the development of more innovative working methods.